Biblio
Export 497 results:
Author [ Title] Type Year Filters: First Letter Of Keyword is N [Clear All Filters]
“Nutrition: Review on the Possible Treatment for Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 867-883, 2018.
, “Nutritional Status is Associated with Faster Cognitive Decline and Worse Functional Impairment in the Progression of Dementia: The Cache County Dementia Progression Study1.”, J Alzheimers Dis, vol. 52, no. 1, pp. 33-42, 2016.
, “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
, “Odor Discrimination as a Marker of Early Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 3, pp. 1169-1178, 2023.
, “Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 2, pp. 547-57, 2016.
, “One-Year Aerobic Exercise Reduced Carotid Arterial Stiffness and Increased Cerebral Blood Flow in Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 80, no. 2, pp. 841-853, 2021.
, “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”, Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
, “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”, Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
, “Oral Health Status in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Data from the Zabút Aging Project.”, J Alzheimers Dis, vol. 87, no. 1, pp. 173-183, 2022.
, “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
, “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
, “Pain Assessment in Elderly with Behavioral and Psychological Symptoms of Dementia.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1217-25, 2016.
, “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
, “Palmitoylethanolamide Blunts Amyloid-β42-Induced Astrocyte Activation and Improves Neuronal Survival in Primary Mouse Cortical Astrocyte-Neuron Co-Cultures.”, J Alzheimers Dis, vol. 61, no. 1, pp. 389-399, 2018.
, “Palmomental Reflex a Relevant Sign in Early Alzheimer's Disease Diagnosis?”, J Alzheimers Dis, vol. 49, no. 4, pp. 1135-41, 2016.
, “Pathogenesis, Animal Models, and Drug Discovery of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 4, pp. 1265-1301, 2023.
, “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 295-307, 2018.
, “Pauses During Autobiographical Discourse Reflect Episodic Memory Processes in Early Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 687-98, 2016.
, “PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 295-302, 2016.
, “PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 295-302, 2016.
, “Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 51, no. 3, pp. 867-73, 2016.
, “Performance on Specific Cognitive Domains and Cause of Death: A Prospective Population-Based Study in Non-Demented Older Adults (NEDICES).”, J Alzheimers Dis, vol. 51, no. 2, pp. 533-44, 2016.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
,